Efficacy and safety of <scp>CT</scp> ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial
CT-868 1.75 to 4.0 mg yielded robust, clinically meaningful decreases in HbA1c, supporting potent glycaemic-lowering effects and improved key lipid parameters in participants with overweight/obesity and T2D, despite modest weight loss. CT-868 was well tolerated, supporting future investigation of higher doses to maximize weight loss.
Authors
- Gabriele E. Sonnenberg (ORCID: https://orcid.org/0000-0002-1320-3128)
- Damian Bialonczyk (ORCID: https://orcid.org/0000-0001-9369-8193)
- José Gerardo González‐González (ORCID: https://orcid.org/0000-0002-6609-9483)
- Raymundo Garcia Cota (ORCID: https://orcid.org/0000-0002-1463-3568)
- FEDERICO A. ARGÜELLES-TELLO (ORCID: https://orcid.org/0000-0001-5393-872X)
- Juan P. Frías (ORCID: https://orcid.org/0000-0001-9486-1255)
- Manu V. Chakravarthy (ORCID: https://orcid.org/0000-0002-3699-150X)
- Jingtao Wu
- Stig K. Hansen
- Michael Elliott
- Luis F. Acosta
Institutions
- Universidad Autónoma de Nuevo León (MX)
- Akebia Therapeutics (United States) (US)
- Carmot Therapeutics (United States) (US)
- Universidad de Comunicación Avanzada (MX)
- Charles R. Drew University of Medicine and Science (US)
- La Roche College (US)
- University of Monterrey (MX)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1111/dom.70006
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29